Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?

Yologlu, Saim; evren, bahri; Topaloğlu, Ömercan; Sahin, ibrahim; Sahin, Selale

doi:10.5455/annalsmedres.2019.11.712

Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?

Ömercan TOPALOĞLU, (İnönü Üniversitesi, Tıp Fakültesi, Endokrinoloji Anabilim Dalı, Malatya, Türkiye)

Bahri EVREN, (İnönü Üniversitesi, Tıp Fakültesi, Endokrinoloji Anabilim Dalı, Malatya, Türkiye)

Saim YOLOĞLU, (İnönü Üniversitesi, Tıp Fakültesi, Biyoistatistik Anabilim Dalı, Malatya, Türkiye)

Şelale ŞAHİN, (Halk Sağlığı Merkezi, Malatya, Türkiye)

İbrahim ŞAHİN (İnönü Üniversitesi, Tıp Fakültesi, Endokrinoloji Anabilim Dalı, Malatya, Türkiye)

Annals of Medical Research

0 0

Yıl: 2020 Cilt: 27 Sayı: 2 Sayfa Aralığı: 648 - 656 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2019.11.712 İndeks Tarihi: 17-10-2020

Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?

Öz:

Aim: Long term control of glucotoxicity was shown to increase the secretion of insulin and C-peptide (Cp). We aimed to investigatethe change in Cp levels after short term glycemic control in patients with uncontrolled type 2 diabetes mellitus (DM).Material and Methods: Patients with type 2 DM with uncontrolled hyperglycemia were included. Basal fasting Cp levels weremeasured both at admission (Cp-admission) and after control of hyperglycemia prior to discharge (Cp-discharge). Cp-differencewas calculated as (Cp-discharge)-(Cp-admission). The patients were divided as group 1 (positive Cp-difference) and group 2(negative Cp-difference), and group A (Cp-difference ≥+0.5) and group B (Cp-difference ≤-0.5).Results: Of the patients (n=123), 61.8% had positive Cp-difference, and mean Cp-differences were 0.16 (±1.59), 0.96 (±1.03), and-1.11 (±1.51) in all patients, group1 and 2; respectively (p=0.001). Mean body weight, creatinine and Cp-discharge were higher ingroup 1(p=0.045, p=0.013, p=0.001; respectively). Mean age, body mass index(BMI), diabetes duration, hospitalization, proteinuria,fasting and postprandial glucose, glucose-discharge, HbA1c, lipids, TSH, free T4, Cp-admission were similar in group 1 and 2.Cpdifference was correlated positively with Cp-discharge(p=0.001), negatively with Cp-admission (p=0.001). There were no significantdifferences between subgroups (age, BMI, diabetes duration, use of secretagogue, diabetic ketaoacidosis history, HbA1c (<10 or≥10%), hyperlipidemia, microvascular complication) regarding to Cp-difference. Positive predictors of positive Cp-difference werecardiovascular disease (p=0.004; Odds Ratio(OR)=3.006) and higher Cp-discharge(p=0.001; OR=6.420);positive predictors of Cpdifference ≥+0.5 were male, lower Cp-admission and higher Cp-discharge.Conclusion: Our results indicate that short-term glycemic control has little but significant positive effect on basal Cp. Havingcardiovascular disease was positive predictor for positive Cp-difference.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Forst T, Kunt T, Pohlmann T, et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998;101:2036-41.
2. Nakamura H, Jinzu H, Nagao K, et al. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diabetes;1:4:e133.
3. Lappas M, Jinks D, Ugoni A, et al. Postpartum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus. J Diabetes 2014.
4. Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes 2014;5:505-10.
5. Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215-21.
6. Kosaka K, Akanuma Y. Heterogeneity of plasma IRI responses in patients with IGT. Diabetologia 1980;18:347-48.
7. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984;26:44-9.
8. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-5.
9. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced beta-cell mass and expression of oxidative stressrelated DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002;45:85-96.
10. Butler AE, Janson J, Bonner-Weir S, et al.β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-10.
11. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-60.
12. Clark A, Cooper GJ, Lewis CE, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987;2:231-4.
13. Eizirik DL, Korbutt GS, Hellerström C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 1992;90:1263-12.
14. Marshak S, Leibowitz G, Bertuzzi F, et al. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 1999;48:1230-6.
15. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces β-cell apoptosis via upregulation of the Fasreceptor in human islets. Diabetes 2001;50:1683-90.
16. Federici M, Hribal M, Perego L, et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001;50:1290-301.
17. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008;29:42-61.
18. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010;140:900-17.
19. Oslowski CM, Hara T, O’Sullivan-Murphy B, et al. Thioredoxin interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab 2012;16:265-73.
20. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018 Diabetes Care 2018;41(Supplement 1):13-27.
21. Jurgens CA, Toukatly MN, Fligner CL, et al. β-Cell loss and β- cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011;178: 2632-40.
22. El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death. Endocrinology 2003;144:4154-63.
23. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
24. Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulinbased versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009;32:1789-95.
25. Robertson RP, Harmon J, Tran PO, et al. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-7.
26. Poitout V, Robertson RP. Glucolipotoxicity: Fuel excess and β-cell dysfunction. Endocr Rev 2008;29:351–66. 27. Kim JW, Yoon KH. Glucolipotoxicity in pancreatic β-Cells. Diabetes Metab J 2011;35:444-50.
28. Poitout V, Olson LK, Robertson RP. Chronic exposure of betaTC- 6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J Clin Invest 1996;97:1041-6.
29. van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabetes Res Clin Pract 2011;93Suppl 1:37- 46.
30. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-12.
31. Glaser B, Leibovitz G, Nesher R, Hartling S, Binder C, Cerasi E 1988 Improved _-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol 118:365–73.
32. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 2008;371:1753–60.
33. Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab 2014;19:872–82.
34. Nakayama H, Kato T, Nakayama S, et al. Cross-sectional and Longitudinal Analyses of Factors Contributing to the Progressive Loss of the β-cell Function in Type 2 Diabetes.Intern Med 2015;54:1971-6.
35. Giroix MH, Irminger JC, Lacraz G, et al. Hypercholesterolaemia, signs of islet microangiopathy and altered angiogenesis precede onset of type 2 diabetes in the Goto-Kakizaki (GK) rat. Diabetologia 2011;54:2451-62.
36. Fujiwara D, Takahashi K, Suzuki T, et al. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C peptide values before and after short-term intensive insulin therapy.J Diabetes Investig 2013;4:618-25.
37. Crisman M, Lucchetta L, Luethi N, et al. The effect of insulin administration on c-peptide in critically ill patients with type 2 diabetes.Ann Intensive Care. 2017;7:50.
38. Nathan DM, Singer DE, Hurxthal K, et al. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341.
39. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30:803–17.
40. Chima RS, LaMontagne T, Piraino G, et al. C-peptide, a novel inhibitor of lung inflammation following hemorrhagic shock. Am J Physiol Lung Cell Mol Physiol 2011;300:L730–9.

APA	Topaloğlu Ö, evren b, Yologlu S, Sahin S, Sahin i (2020). Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. , 648 - 656. 10.5455/annalsmedres.2019.11.712
Chicago	Topaloğlu Ömercan,evren bahri,Yologlu Saim,Sahin Selale,Sahin ibrahim Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. (2020): 648 - 656. 10.5455/annalsmedres.2019.11.712
MLA	Topaloğlu Ömercan,evren bahri,Yologlu Saim,Sahin Selale,Sahin ibrahim Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. , 2020, ss.648 - 656. 10.5455/annalsmedres.2019.11.712
AMA	Topaloğlu Ö,evren b,Yologlu S,Sahin S,Sahin i Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. . 2020; 648 - 656. 10.5455/annalsmedres.2019.11.712
Vancouver	Topaloğlu Ö,evren b,Yologlu S,Sahin S,Sahin i Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. . 2020; 648 - 656. 10.5455/annalsmedres.2019.11.712
IEEE	Topaloğlu Ö,evren b,Yologlu S,Sahin S,Sahin i "Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?." , ss.648 - 656, 2020. 10.5455/annalsmedres.2019.11.712
ISNAD	Topaloğlu, Ömercan vd. "Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?". (2020), 648-656. https://doi.org/10.5455/annalsmedres.2019.11.712

APA	Topaloğlu Ö, evren b, Yologlu S, Sahin S, Sahin i (2020). Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. Annals of Medical Research, 27(2), 648 - 656. 10.5455/annalsmedres.2019.11.712
Chicago	Topaloğlu Ömercan,evren bahri,Yologlu Saim,Sahin Selale,Sahin ibrahim Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. Annals of Medical Research 27, no.2 (2020): 648 - 656. 10.5455/annalsmedres.2019.11.712
MLA	Topaloğlu Ömercan,evren bahri,Yologlu Saim,Sahin Selale,Sahin ibrahim Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. Annals of Medical Research, vol.27, no.2, 2020, ss.648 - 656. 10.5455/annalsmedres.2019.11.712
AMA	Topaloğlu Ö,evren b,Yologlu S,Sahin S,Sahin i Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. Annals of Medical Research. 2020; 27(2): 648 - 656. 10.5455/annalsmedres.2019.11.712
Vancouver	Topaloğlu Ö,evren b,Yologlu S,Sahin S,Sahin i Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. Annals of Medical Research. 2020; 27(2): 648 - 656. 10.5455/annalsmedres.2019.11.712
IEEE	Topaloğlu Ö,evren b,Yologlu S,Sahin S,Sahin i "Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?." Annals of Medical Research, 27, ss.648 - 656, 2020. 10.5455/annalsmedres.2019.11.712
ISNAD	Topaloğlu, Ömercan vd. "Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?". Annals of Medical Research 27/2 (2020), 648-656. https://doi.org/10.5455/annalsmedres.2019.11.712